iwCLL 2019 | MURANO: outcomes after the end of treatment

John Seymour

John Seymour, MBBS, PhD, Peter MacCallum Cancer Center, Melbourne, Australia, discusses the outcomes after the end of treatment in patients on the MURANO study (NCT02005471), with reference to the use of measurable residual disease (MRD). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Share this video